Indalo Therapeutics
St. Louis, United States · Founded 2016 · $26.0M raised
- Headquarters
- St. Louis, Missouri
- Founded
- 2016
- Business Model
- B2B
- Total Funding
- $26.0M
- Last Round
- $26.0M Series AAug 2017
- Rounds
- 1
About
Indalo Therapeutics is a St. Louis-based biopharmaceutical company formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics. The company discovers and develops integrin antagonist therapies, including lead candidate IDL-2965, to treat serious fibrotic diseases such as idiopathic pulmonary fibrosis and NASH. Indalo has advanced its programs through Phase 1 clinical trials, backed by an experienced management team, strong intellectual property, and investors including Atlas Venture and F-Prime Capital.
Summary
Indalo Therapeutics is a Biotech company based in St. Louis, United States, founded in 2016. It has raised $26.0M in total across 1 round, most recently a $26.0M Series A round in Aug 2017. Investors include Atlas Venture, F-Prime Capital and Missouri Technology Co.
Funding History
Aug 2017
Investors
Similar Companies
China's leading blood products manufacturer
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Specialty pharmaceutical company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/indalo-therapeutics"><img src="https://indexed.vc/api/badge/company/indalo-therapeutics" alt="Indalo Therapeutics on Indexed.vc" width="260" height="76" /></a>